Nanjing Huawei Pharmaceutical Technology Development

Nanjing Huawei Pharmaceutical Technology Development is a prominent Chinese contract research organization (CRO) and pharmaceutical technology developer specializing in the research and development of generic and innovative drugs. Founded in 2000 and headquartered in Nanjing, the company provides a full suite of services including drug discovery, CMC (Chemistry, Manufacturing, and Controls), clinical trial management, and regulatory registration. In 2016, the company was acquired by Nanjing King-Friend Biochemical Pharmaceutical (Kingfriend), a move that integrated its R&D expertise with Kingfriend's manufacturing and global commercialization capabilities. Huawei Pharma is particularly recognized for its expertise in high-end injectables, complex formulations, and sustained-release technologies. The company has successfully developed hundreds of drug candidates for domestic and international clients, maintaining a leading position in the Chinese pharmaceutical outsourcing market.